Price movement over the last 24 hours
Alcon AG vs Target Corporation — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while Target Corporation trades at $132.46 (market cap $57.93B). The key difference: Target Corporation is the larger of the two by market cap, and Target Corporation pays the higher dividend (3.64%). Which is the better fit depends on your goals.
| ALC | TGT | |
|---|---|---|
Market Cap | $32.69B | $57.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $141.19 |
52-Week Low | $62.02 | $83.68 |
Enterprise Value | $36.28B | $73.23B |
Dividend Yield | 0.54% | 3.64% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Target trades at $127.55, down 2.04% today, with technical indicators showing bearish momentum. The stock maintains solid fundamentals with a P/E of 16.66 and net income margin of 3.24%, supported by three consecutive quarterly EPS beats. Recent news highlights Target's marketplace expansion and consumer resilience focus amid retail sector volatility.
The outlook remains balanced with a consensus price target of $137 offering 7.4% upside potential, though bearish technical signals and competitive pressures pose risks. Strong cash flow generation and dividend payments provide shareholder stability while execution on growth initiatives will be critical for sustained performance.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →